Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/13/2003WO2003020889A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003WO2003020760A1 Modulation of the expression of toll-like receptors influences neurodegeneration and neuroprotection in the human central nervous system
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020749A2 Ncam binding compounds
03/13/2003WO2003020724A1 Polycyclic guanine phosphodiesterase v inhibitors
03/13/2003WO2003020723A1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
03/13/2003WO2003020719A1 1,3-benzothiazinone derivatives and use thereof
03/13/2003WO2003020716A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003WO2003020707A1 Optical isomers of an iloperidone metabolite
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020370A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020314A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
03/13/2003WO2003020289A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
03/13/2003WO2003020287A2 Methods for the treatment of chronic pain anc compositions therefor
03/13/2003WO2003020282A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003WO2003020281A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/13/2003WO2003020275A1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
03/13/2003WO2003020273A2 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
03/13/2003WO2003020269A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020217A2 Novel pyrazole analogs acting on cannabinoid receptors
03/13/2003WO2003020216A1 Methods for inhibiting cognitive deterioration in adults with down's syndrome
03/13/2003WO2003020212A2 Treatment for central nervous system disorders
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2003020005A2 Lp mammalian proteins; related reagents
03/13/2003WO2003004472A8 Arylamines for the treatment of conditions associated with gsk-3
03/13/2003WO2002100354A3 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/13/2003WO2002094774A3 Oxcarbazepine dosage forms
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002076950A3 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002066469A3 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
03/13/2003WO2002066427A3 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/13/2003WO2002062832A3 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
03/13/2003WO2002058706A3 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
03/13/2003WO2002055078A3 Use of chromanes for treating parkinson's disease
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042454A3 Gene involved in schizophrenia
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002041878A3 Titratable dosage transdermal delivery system
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036829A3 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
03/13/2003WO2002036554A3 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002026984A3 Potassium channel interactors and uses therefor
03/13/2003WO2002024194A3 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
03/13/2003WO2002020757A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002020056A3 Methods and compositions for producing a neurosalutary effect in a subject
03/13/2003WO2002011750A3 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
03/13/2003WO2002011708A3 Methods for inducing apolipoprotein e secretion
03/13/2003WO2002010347A3 Directed differentiation of embryonic cells
03/13/2003WO2002005798A3 Pharmaceutical compositions for treating neurological disorders
03/13/2003WO2002003684A3 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
03/13/2003WO2002002635A3 Isolated human ion channel proteins, nucleic acid molecules encoding them, and uses thereof
03/13/2003WO2002000913A3 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
03/13/2003WO2001096598A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
03/13/2003US20030050484 A 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile is alkylated with a compound which may be converted to a dimethylaminopropyl group
03/13/2003US20030050466 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cancer or autoimmune diaseses
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050344 Thyroid hormones or their salts in capsule or in swallowable uniform soft-gel gelatin matrices for treatment of hypothyroidism
03/13/2003US20030050337 Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5- dimethyl-5H-furan-2-one
03/13/2003US20030050335 For prevent and treatment of neurodegenerative disorders such as stroke or Alzheimer's disease
03/13/2003US20030050316 An amine compound of phenyl or hetero ring for treating Alzheimer's disease
03/13/2003US20030050311 A novel phenyl oxazoles, thiazoles, oxazolines, oxadiazoles or benzoxazoles for treating neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, amytrophic lateral sclerosis or cerebral trauma
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050309 A gelatinase inhibitor for modulating the activity of a dopamine, serotonin, or norepinephrine receptor or transporter
03/13/2003US20030050308 Eltoprazine hydrochloride (1-(2,3-dihyro-1,4-benzodioxin-5-yl) piperazine hydrochloride), a phenylpiperazine derivative
03/13/2003US20030050307 Treating certain psychiatric and neurological disorders; anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and psychosis
03/13/2003US20030050306 Novel heteroaryl derivatives, their preparation and use
03/13/2003US20030050304 Therapeutic compounds
03/13/2003US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent
03/13/2003US20030050300 Therapeutic 5-HT ligand compounds
03/13/2003US20030050299 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050289 Combination of drospirenone and an estrogen sulphamate for HRT
03/13/2003US20030050281 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
03/13/2003US20030050273 Administering recombinant adeno-associated virus virions with a polynucleotide encoding a glial cell line-derived neutrotrophic factor polypeptide operably linked to expression control
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050269 Polynucleotides and polypeptides of the erythropoietin gene
03/13/2003US20030050262 Inhibition of neurodegeneration
03/13/2003US20030050257 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
03/13/2003US20030050245 A protein molecule that is a cofactor of tissue plasminogen activator and has a residue of lysine and/or arginine or an equivalent; angiogenesis inhibitors; antiinflammatory agents; antitumor agents; aging; degrads amyloid
03/13/2003US20030050242 Protein polymerization inhibitors and methods of use
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030050230 A nucleic acid encoding a family (title) of kinases from a group of sixteen polypeptides; identifying a substance that modulates kinase activity; autoimmune diseases; organ transplantation, cardiovascular disease, stroke, renal failure
03/13/2003US20030050228 Administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes
1 ... 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 ... 1833